[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536890":3},{"organization":4,"armGroups":7,"interventions":43,"overallOfficials":68,"centralContacts":72,"locations":76,"responsibleParty":150,"collaborators":49,"id":152,"slug":49,"hasResults":153,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":49,"eligibilityCriteria":157,"healthyVolunteers":153,"sex":158,"minAge":159,"maxAge":49,"enrollmentInfo":160,"targetDuration":49,"studyType":163,"phases":164,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":92,"whyStopped":49,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},{"fullName":5,"class":6},"Pliant Therapeutics, Inc.","INDUSTRY",[8,15,19,23,27,31,35,39],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1 Dose Escalation - 250 mg BID","EXPERIMENTAL","Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors",[13,14],"Drug: PLN-101095","Drug: Pembrolizumab",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 1 Dose Escalation - 500 mg BID","PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Part 1 Dose Escalation - 1000 mg BID","PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Part 1 Dose Escalation - 1000 mg TID","PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors",[13,14],{"label":28,"type":10,"description":29,"interventionNames":30},"Part 1 Dose Escalation - 2000 mg BID","PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors",[13,14],{"label":32,"type":10,"description":33,"interventionNames":34},"Part 2 Dose Expansion - NSCLC","PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC)",[13,14],{"label":36,"type":10,"description":37,"interventionNames":38},"Part 2 Dose Expansion - ccRCC","PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC)",[13,14],{"label":40,"type":10,"description":41,"interventionNames":42},"Part 2 Dose Expansion - TMB-high solid tumors","PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors",[13,14],[44,50,53,56,59,62,64],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"DRUG","PLN-101095","PLN-101095 250 mg BID",[9],null,{"type":45,"name":46,"description":51,"armGroupLabels":52,"otherNames":49},"PLN-101095 500 mg BID",[16],{"type":45,"name":46,"description":54,"armGroupLabels":55,"otherNames":49},"PLN-101095 1000 mg BID",[20],{"type":45,"name":46,"description":57,"armGroupLabels":58,"otherNames":49},"PLN-101095 1000 mg TID",[24],{"type":45,"name":46,"description":60,"armGroupLabels":61,"otherNames":49},"PLN-101095 2000 mg BID",[28],{"type":45,"name":46,"description":46,"armGroupLabels":63,"otherNames":49},[32,40,36],{"type":45,"name":65,"description":66,"armGroupLabels":67,"otherNames":49},"Pembrolizumab","Pembrolizumab (KEYTRUDA) 200 mg IV Q3W",[20,24,28,9,16,32,40,36],[69],{"name":70,"affiliation":5,"role":71},"Pliant Therapeutics Medical Monitor","STUDY_DIRECTOR",[73],{"name":70,"role":74,"phone":75,"phoneExt":49,"email":75},"CONTACT","clintrials@pliantrx.com",[77,90,103,115,127,138],{"facility":78,"status":79,"city":80,"state":81,"zip":82,"country":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":49},"Yale University","ACTIVE_NOT_RECRUITING","New Haven","Connecticut","06511","United States",{"type":85,"coordinates":86},"Point",[87,88],-72.92816,41.30815,{"lat":88,"lon":87},{"facility":91,"status":92,"city":93,"state":94,"zip":95,"country":83,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Winship Cancer Institute of Emory University","RECRUITING","Atlanta","Georgia","30322",{"type":85,"coordinates":97},[98,99],-84.38798,33.749,{"lat":99,"lon":98},[102],{"name":70,"role":74,"phone":49,"phoneExt":49,"email":75},{"facility":104,"status":92,"city":105,"state":106,"zip":107,"country":83,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"South Texas Accelerated Research Therapeutics (START)","Grand Rapids","Michigan","49546",{"type":85,"coordinates":109},[110,111],-85.66809,42.96336,{"lat":111,"lon":110},[114],{"name":70,"role":74,"phone":49,"phoneExt":49,"email":75},{"facility":116,"status":92,"city":117,"state":118,"zip":119,"country":83,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"NEXT Austin","Austin","Texas","78758",{"type":85,"coordinates":121},[122,123],-97.74306,30.26715,{"lat":123,"lon":122},[126],{"name":70,"role":74,"phone":49,"phoneExt":49,"email":75},{"facility":128,"status":92,"city":129,"state":118,"zip":130,"country":83,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"University of Texas MD Anderson Cancer Center","Houston","77030",{"type":85,"coordinates":132},[133,134],-95.36327,29.76328,{"lat":134,"lon":133},[137],{"name":70,"role":74,"phone":49,"phoneExt":49,"email":75},{"facility":139,"status":92,"city":140,"state":141,"zip":142,"country":83,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"NEXT Virginia","Fairfax","Virginia","22031",{"type":85,"coordinates":144},[145,146],-77.30637,38.84622,{"lat":146,"lon":145},[149],{"name":70,"role":74,"phone":49,"phoneExt":49,"email":75},{"type":151,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100536890",false,"NCT06270706","A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors","A Phase 1a\u002F1b Multicenter, Open-label Dose Escalation\u002FExpansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on an Immune Checkpoint Inhibitor (FORTIFY)","Inclusion Criteria:\n\n1. Has histologically or cytologically confirmed advanced or metastatic solid tumor\n2. Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies\n3. Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)\n4. Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment\n5. At least 1 measurable lesion, as defined by RECIST v1.1\n6. Estimated survival of ≥3 months\n7. Have adequate bone marrow and organ function.\n8. A female participant is eligible to participate if she is not pregnant, not breastfeeding\n\nExclusion Criteria:\n\n1. Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab\n2. Has a known additional malignancy that is progressing or has required active treatment within the past 2 years\n3. Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy\n4. Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications\n5. Has a diagnosis of immunodeficiency or use of systemic steroids \\>10 mg\u002Fday\n6. Has an active autoimmune disease that has required systemic treatment in the past 2 years\n7. Has known active CNS metastases (brain and\u002For leptomeningeal metastases)\n8. Has significant cardiac disease\n9. Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)\n10. Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095","ALL","18 Years",{"count":161,"type":162},124,"ESTIMATED","INTERVENTIONAL",[165],"PHASE1","This is a Phase 1a\u002F1b, dose-escalation\u002Fexpansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \\[primary resistance\\]) or relapsed \\[secondary resistance\\]) after at least 3 months from the start of treatment with pembrolizumab.\n\nThe study will consist of 2 main parts:\n\n* Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration\n* Part 2: Dose-expansion cohorts using Simon's 2-stage design",[168],"Advanced or Metastatic Solid Tumor",[170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,65,186],"Advanced Solid Tumors Cancer","Anal Carcinoma","Biliary tract carcinoma (BTC)","Cholangiocarcinoma","Clear cell renal cell carcinoma (ccRCC)","Colorectal Cancer","Endometrial Cancer","Gallbladder","Head and Neck Squamous Cell Cancer (HNSCC)","Melanoma","Non-small cell lung cancer (NSCLC)","Ovarian Carcinoma","Triple Negative Breast Cancer (TNBC)","Tumor mutational burden (TMB)-high tumors","TMB-low tumors","Urothelial Carcinoma","Immunotherapy","2026-04-15",{"date":189,"type":190},"2026-04-20","ACTUAL",{"date":192,"type":190},"2023-08-30",{"date":194,"type":162},"2030-06",{"name":5,"class":6},6]